HOME > COLUMN

COLUMN

Maurer's Healthcare Insight (100)

October 27, 2008
Maurer's Healthcare Insight (99)

September 29, 2008
Maurer's Healthcare Insight (98)

August 25, 2008
Maurer's Healthcare Insight (97)

July 28, 2008
Maurer's Healthcare Insight (96)

June 23, 2008
Maurer's Healthcare Insight (95)

May 19, 2008
Maurer's Healthcare Insight (94)

March 10, 2008
Maurer's Healthcare Insight (93)

February 18, 2008
Maurer's Healthcare Insight (92)

January 21, 2008
Maurer's Healthcare Insight (91)

December 24, 2007
Maurer's Healthcare Insight (90)

November 5, 2007
Maurer's Healthcare Insight (89)

October 8, 2007
Maurer's Healthcare Insight (88)

August 6, 2007
Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer

June 4, 2007
Maurer's Healthcare Insight (86)

May 28, 2007
Maurer's Healthcare Insight (85)

April 16, 2007
Maurer's Healthcare Insight (84)

March 26, 2007
Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer

March 12, 2007
Maurer's Healthcare Insight (83)

February 19, 2007
2006: When the Pendulum Swung P. Reed Maurer

January 8, 2007

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…